Plain-English translation of NCT06194734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called works better than standard chemotherapy for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) that has already been treated with immunotherapy and at least one other chemotherapy. You would be randomly assigned to receive either or one of three standard chemotherapy drugs, and researchers will compare how well each treatment works and what side effects patients experience.
Many patients with advanced esophageal cancer stop responding to current treatments like immunotherapy and standard chemotherapy. This trial is testing whether this medication offers a new option that could help patients whose cancer has progressed despite previous treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either or one of three standard chemotherapy options. You will receive your assigned treatment until your cancer progresses, you experience intolerable side effects, or your doctor recommends stopping. The trial will follow you at multiple cancer centers, and researchers will monitor your tumor response using imaging scans (following RECIST guidelines) and assess any side effects you experience.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Enrollment target
~490 participants
Started
February 2024
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jing Huang, Ph.D
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.